ZEMBRACE SYMTOUCH Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zembrace Symtouch, and when can generic versions of Zembrace Symtouch launch?
Zembrace Symtouch is a drug marketed by Tonix Meds and is included in one NDA. There are two patents protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in ZEMBRACE SYMTOUCH is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zembrace Symtouch
A generic version of ZEMBRACE SYMTOUCH was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZEMBRACE SYMTOUCH?
- What are the global sales for ZEMBRACE SYMTOUCH?
- What is Average Wholesale Price for ZEMBRACE SYMTOUCH?
Summary for ZEMBRACE SYMTOUCH
| International Patents: | 6 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 115 |
| Patent Applications: | 2,223 |
| Drug Prices: | Drug price information for ZEMBRACE SYMTOUCH |
| What excipients (inactive ingredients) are in ZEMBRACE SYMTOUCH? | ZEMBRACE SYMTOUCH excipients list |
| DailyMed Link: | ZEMBRACE SYMTOUCH at DailyMed |
Pharmacology for ZEMBRACE SYMTOUCH
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
US Patents and Regulatory Information for ZEMBRACE SYMTOUCH
ZEMBRACE SYMTOUCH is protected by two US patents.
Patents protecting ZEMBRACE SYMTOUCH
Pharmaceutical composition for treating migraine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MIGRAINE
Pharmaceutical composition for treating migraine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MIGRAINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonix Meds | ZEMBRACE SYMTOUCH | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223-001 | Jan 28, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tonix Meds | ZEMBRACE SYMTOUCH | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223-001 | Jan 28, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEMBRACE SYMTOUCH
See the table below for patents covering ZEMBRACE SYMTOUCH around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3331524 | COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2017023361 | ⤷ Sign Up | |
| Canada | 2994748 | COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
